Latigo Biotherapeutics is focused on developing innovative non-opioid pain medications that aim to address the significant unmet need for effective pain management solutions. The company employs a unique approach that targets pain at its source, specifically through the modulation of ion channels, such as Nav1.8, which is a validated target for human pain. By utilizing sophisticated models and human biological insights, Latigo's research emphasizes the importance of understanding human genetics and pharmacology to elucidate the mechanisms of action for their pain therapies. Their lead program, LTG-001, has shown promising results in Phase 1 clinical trials, demonstrating rapid absorption and tolerability, which are critical for effective pain relief.

Latigo's drug discovery process is characterized by advanced techniques in computer-assisted design and rigorous evaluation in human model systems. The company prioritizes the optimization of drug potency and selectivity while ensuring that the compounds effectively engage with the target in human neurons. Their strategy includes measuring drug biodistribution to ensure that the medications reach the target tissues while minimizing central nervous system exposure to enhance safety. This comprehensive approach aims to deliver rapid-acting pain relief without the risk of addiction, ultimately restoring quality of life for patients suffering from acute and chronic pain.

United States

Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures. 

Latigo Biotherapeutics

Company Details